Biochemist by education, Mrs. Sybil Dahan began her career in the pharmaceutical industry in 1989. She held many positions in Sales and Marketing in Canada. She spent most of her career with Abbott Laboratories (now AbbVie) which lead her to work in the USA and Latin America, and then in Sweden as General Manager and Chairman of the Board of Abbott Scandinavia. Mrs. Dahan became one of the first foreign General Managers in Sweden to become an elected Board member of the Swedish Pharmaceutical Trade Association (LIF). She returned to Canada in 2008, but soon thereafter leaves Big Pharma to explore the world of small to medium size businesses. She joined Triton Pharma Inc. as President, and following the sale of Triton Pharma Inc. to Paladin Labs Inc. in December 2013, Mrs. Dahan embarks on the third phase of her career’s journey – entrepreneurship – to become co-owner of Aspri Pharma Canada Inc. and more recently Altius Healthcare; importer and distributor of pharmaceutical products managing over thirty million dollars of annual sales. Mrs. Dahan is recognized by her peers as being a visionary and energetic senior level leader who effectively manages all aspects of commercial operations.
Jacques Bernier has been part of FOLIA BIOTECH team from its inception and acted as its CEO from 2008 to 2014 after several successful years in the business world. He was responsible for establishing FOLIA’s Business Plan with a new vision. He raised more than $11.0 M in funding. Under his leadership, the company successfully completed the preclinical program and the first clinical trial in human (Phase I) of its lead product FB-631. In addition, the company has developed research collaborations with many companies or organizations. Since 2014 he is a member of the Board of FOLIA as a Director and Chair of the finance and audit committee.
Before joining FOLIA BIOTECH, he was President and CEO of Gescopharm Inc a company involved in the operation of retail pharmacy. During these years, he gained extensive experience in management and business development and an excellent knowledge of the pharmaceutical industry. He was a member of the Board of Familiprix a group of nearly 300 pharmacies. First, as member of the marketing committee for advertising, marketing and sales strategy and then Vice President of the Board and Vice President of the Finance committee where he was responsible for budget and financial statements of the company.
He holds a Bachelor’s Degree in pharmacy from Université Laval, Quebec City (1984). In 2007, he completed his MBA with a concentration in pharmaceutical management at Université Laval. Within this program, he gained a distinctive competence of managing organizations in the pharmaceutical field, as the biotechnology sector. In 2008, he completed a graduate program in pharmaceutical product development. This training allowed him to get familiar with each step of the clinical process, from pre-clinical testing to phase IV clinical studies.
He is a member of the Board and Treasurer of Montmagny Hospital Foundation. He is a member of committees for several charitable activities.
Tarique Saiyed is a Chartered Accountant from the Institute of Chartered Accountants of India and holds a bachelor’s in commerce with a major in accounting and finance from the University of Allahabad, India. Mr. Saiyed has over 21 years of demonstrated experience lending strategic vision to corporate giants across diverse geographies of Europe, Russia, Commonwealth, Middle East and North Africa. He started his Pharmaceutical career with Merck & Co Saudi Arabia in Sep 2000 from where he moved as Finance Director in 2005 to Globalpharma which was Dubai’s first pharmaceutical manufacturing company. From March 2009 to June 2014, Mr. Saiyed worked for Aspen Healthcare FZ LLC in Dubai, United Arab Emirates, as Chief Financial Officer. From July 2014 to July 2017, he managed regional trading hubs for Europe, Middle East and North Africa region as Managing Director for Aspen Pharma Ireland Ltd. in Dublin. Mr. Saiyed then worked from January 2018 to June 2018 as Chief Operating Officer for IXD Consulting Dublin in Ireland and from June to October 2018 as a Consultant for setting up Sunark Pharma in Estonia.
Mr. Bourassa brings over 35 years of experience of financing and entrepreneurship.
He held different responsibilities in the pharmaceutical industry and the financing industry before joining the National Research Council (NRC) in 1999.
He was an Advisor at the Industrial Research Assistance Program (IRAP) of the NRC until his retirement in 2016. Pierre has contributed to the financing of more than 250 projects over the years, most of them related to the life sciences industry. He participated to numerous investment committee, advisory boards and acted as an observer to many boards. Pierre is recognized for his extensive network within the industry and his role as advisor to many entrepreneurs.
In 2016, Pierre created Equinvest Management Inc. a management consulting group focusing on strategic issues.
Pierre holds a B. Sc. in Biochemistry (Sherbrooke), a degree in management (HEC Montreal) and an MBA in bio-industries management (UQAM).
Dr. Claude Vezeau is an experienced leader and entrepreneur with a breath of experience in academia, life sciences, biotechnology and pharmaceutical industries including the start-up and financing of several biotechnology companies. After working in several executive positions in the large pharmaceutical industry, Dr. Vezeau became a partner at BioCapital, a successful investment fund in biotechnology and biopharmaceutical companies. He then joined BioChem Pharma to lead the BioChem Vaccines division. He was the founder of Innodia. He currently serves as an advisor to Aligo Innovation, to Inolife Sciences and to Walter Capital.